Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, USA.
Nature. 2012 Jul 5;487(7405):64-9. doi: 10.1038/nature11220.
A T-cell-mediated immune response is initiated by the T-cell receptor (TCR) interacting with peptide-bound major histocompatibility complex (pMHC) on an infected cell. The mechanism by which this interaction triggers intracellular phosphorylation of the TCR, which lacks a kinase domain, remains poorly understood. Here, we have introduced the TCR and associated signalling molecules into a non-immune cell and reconstituted ligand-specific signalling when these cells are conjugated with antigen-presenting cells. We show that signalling requires the differential segregation of a phosphatase and kinase in the plasma membrane. An artificial, chemically controlled receptor system generates the same effect as TCR–pMHC, demonstrating that the binding energy of an extracellular protein–protein interaction can drive the spatial segregation of membrane proteins without a transmembrane conformational change. This general mechanism may extend to other receptors that rely on extrinsic kinases, including, as we demonstrate, chimaeric antigen receptors being developed for cancer immunotherapy.
T 细胞介导的免疫反应是由 T 细胞受体(TCR)与感染细胞上的肽结合主要组织相容性复合物(pMHC)相互作用而引发的。这种相互作用触发 TCR 细胞内磷酸化的机制,而 TCR 缺乏激酶结构域,仍然知之甚少。在这里,我们将 TCR 和相关信号分子引入非免疫细胞中,并在这些细胞与抗原呈递细胞缀合时重建配体特异性信号。我们表明,信号传导需要在质膜中差异分离磷酸酶和激酶。一种人工的、化学控制的受体系统产生与 TCR-pMHC 相同的效果,表明细胞外蛋白-蛋白相互作用的结合能驱动膜蛋白的空间分离,而无需跨膜构象变化。这种一般机制可能扩展到其他依赖于外在激酶的受体,包括我们证明的用于癌症免疫治疗的嵌合抗原受体。